SCI Pharmtech, Inc. (TPE:4119)
Taiwan · Delayed Price · Currency is TWD 52.00
-0.30 (-0.57%)
Aug 19, 2026, 1:30 PM CST
SCI Pharmtech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,261 | 1,344 | 1,524 | 1,204 | 899.74 | 864.22 | |
Revenue Growth | -18.83% | -11.81% | 26.54% | 33.83% | 4.11% | -67.86% |
Cost of Revenue | 955.41 | 992.7 | 1,113 | 853.84 | 608.56 | 656.13 |
Gross Profit | 305.16 | 351.03 | 410.67 | 350.32 | 291.18 | 208.09 |
Selling, General & Admin | 163.23 | 157.96 | 169.7 | 140.93 | 132.56 | 104.08 |
Research & Development | 37.91 | 37.82 | 42.68 | 49.09 | 39.65 | 30.35 |
Operating Expenses | 201.14 | 195.78 | 212.38 | 190.02 | 172.21 | 134.43 |
Operating Income | 104.02 | 155.25 | 198.29 | 160.3 | 118.97 | 73.66 |
Interest Expense | -7.52 | -4.94 | -5.54 | -6.29 | -1.07 | -0.04 |
Interest & Investment Income | 1.73 | 5.29 | 9.98 | 6.17 | 6.49 | 10.04 |
Earnings From Equity Investments | -58.47 | -46.63 | -23.73 | -13.84 | -12.56 | -13.55 |
Currency Exchange Gain (Loss) | -25.1 | -25.1 | 22.6 | 2.37 | 27.55 | -15 |
Other Non Operating Income (Expenses) | 60.09 | 16.99 | 10.19 | 6.62 | 4.37 | 24.41 |
EBT Excluding Unusual Items | 74.75 | 100.86 | 211.79 | 155.33 | 143.75 | 79.52 |
Gain (Loss) on Sale of Investments | 1.33 | 1.33 | 3.62 | -1.87 | -14.07 | 2.24 |
Gain (Loss) on Sale of Assets | - | - | - | -0.58 | -1.33 | - |
Other Unusual Items | - | - | - | 0.37 | 101.2 | -16.26 |
Pretax Income | 76.08 | 102.19 | 646.86 | 364.19 | 387.82 | 65.51 |
Income Tax Expense | 15.96 | -5.18 | 112.18 | 69.47 | 79.04 | 9.81 |
Net Income | 60.12 | 107.37 | 534.68 | 294.72 | 308.78 | 55.7 |
Net Income to Common | 60.12 | 107.37 | 534.68 | 294.72 | 308.78 | 55.7 |
Net Income Growth | -87.54% | -79.92% | 81.42% | -4.55% | 454.40% | -84.53% |
Shares Outstanding (Basic) | 121 | 120 | 120 | 109 | 107 | 107 |
Shares Outstanding (Diluted) | 121 | 120 | 120 | 110 | 108 | 108 |
Shares Change | 0.93% | -0.13% | 9.44% | 1.87% | 0.08% | -0.49% |
EPS (Basic) | 0.50 | 0.90 | 4.47 | 2.70 | 2.88 | 0.52 |
EPS (Diluted) | 0.50 | 0.90 | 4.46 | 2.69 | 2.87 | 0.52 |
EPS Growth | -87.65% | -79.86% | 65.80% | -6.27% | 456.63% | -84.53% |
Free Cash Flow | -174.44 | -389.68 | -86.12 | -813.59 | -871.02 | -490.75 |
Free Cash Flow Per Share | -1.44 | -3.25 | -0.72 | -7.42 | -8.10 | -4.57 |
Dividend Per Share | 0.750 | 0.750 | 1.500 | 1.250 | 0.222 | - |
Dividend Growth | -50.00% | -50.00% | 20.00% | 462.56% | -40.00% | - |
Gross Margin | 24.21% | 26.12% | 26.95% | 29.09% | 32.36% | 24.08% |
Operating Margin | 8.25% | 11.55% | 13.01% | 13.31% | 13.22% | 8.52% |
Profit Margin | 4.77% | 7.99% | 35.09% | 24.47% | 34.32% | 6.44% |
Free Cash Flow Margin | -13.84% | -29.00% | -5.65% | -67.56% | -96.81% | -56.79% |
EBITDA | 354.28 | 402.45 | 429.73 | 303.68 | 207.95 | 135.59 |
EBITDA Margin | 28.11% | 29.95% | 28.20% | 25.22% | 23.11% | 15.69% |
D&A For EBITDA | 250.26 | 247.2 | 231.44 | 143.38 | 88.98 | 61.93 |
EBIT | 104.02 | 155.25 | 198.29 | 160.3 | 118.97 | 73.66 |
EBIT Margin | 8.25% | 11.55% | 13.01% | 13.31% | 13.22% | 8.52% |
Effective Tax Rate | 20.98% | - | 17.34% | 19.07% | 20.38% | 14.98% |